Another Game-Changing Announcement Sends (PCSA) Vertical First Thing, Up Approximately 11%
PCSA is cooking with heat early this AM.
Currently up approximately 11%, PCSA dropped some huge breaking news today. Check it out:
Processa Pharmaceuticals Announces PCS12852 Successfully Improves the Clinical Symptoms Associated with Gastroparesis in Phase 2A Trial
- A 0.5 mg daily dose of PCS12852 administered over 28 days in gastroparesis patients successfully improved gastroparesis symptoms in a clinically meaningful way as defined by greater than a 0.5 reduction in the ANMS GCSI-DD score compared to baseline.
- The percentage of patients who met the clinically meaningful change in symptom score was greater in the PCS12852 0.5 mg daily dose group than in the placebo or the PCS12852 0.1 mg daily dose groups.
- Over 28 days the mean gastroparesis symptoms score continually improved more for the 0.5 mg PCS12852 group than the placebo group suggesting that longer treatment than 28 days may result in greater differences in gastroparesis symptoms for a 0.5 mg daily dose of PCS12852 than for placebo.
- The results, in addition to the previously announced improvements in gastric emptying in patients that received the daily dose of 0.5 mg of PCS12852, further support initiating a PCS12852 Phase 2B trial in 2023 for the treatment of gastroparesis.
HANOVER, MD, Dec. 14, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a diversified clinical-stage company developing products to improve survival and/or the quality of life for patients who have an unmet medical need condition, today announced positive top-line results on the clinical symptoms associated with gastroparesis from a 4-week Phase 2A study of PCS12852, which is being developed for the treatment of patients with gastroparesis. The trial was a placebo-controlled, randomized, dose-response study designed to evaluate the safety, efficacy, and pharmacokinetics of two dosage regimens of PCS12852 vs placebo (clinicaltrials.gov identifier NCT05270460). Processa previously announced an improvement in the primary endpoint of the study, the gastric emptying rate, in patients that received a 0.5 mg daily dose of PCS12852. The results from this Phase 2A study also showed that clinically meaningful improvements in gastroparesis symptoms occurred in more patients (i.e., a greater percentage of patients) receiving the PCS12852 0.5 mg daily dose than the placebo daily dose.
Read the full article here.
On top of that, PCSA has also moved above its 50-Day Simple Moving Average on top of it already trading above the 4 other key lines I highlighted in the report below.
Drop everything and get PCSA on your radar now.
Let's dive in. Shall we?
Monday's alert went to blast-off town and I mean early. Like pre-market early.
Brought to your attention on Sunday after closing at $2.86 Friday, your latest champ came out hot in pre-market on breaking news.
At times trading up approximately $1.00 from Friday's close, KWE carried that momentum into the opening bell to shoot to an intraday high of $3.57+.
That comes on the heels of last week's champ that knocked it out of the park from this past Thursday's close to Friday's high.
With an approximate 22%, we got this streak started in style.
Okay. Streak may be an overstatement. I'm thinking you need at least 3 in a row for that.
That's why I want you to check out this new Nasdaq breakout idea.
With it trading in after hours Tuesday above 4 key lines of potential support, having a low float of under 10Mn shares, and an analyst target providing over 300% potential upside at this moment, this Biotech profile requires immediate attention.
For Wednesday, December 14th, there is only one profile to fix your eyes on:
*Processa Pharmaceuticals, Inc. (PCSA)*
Processa Pharmaceuticals develops products that improve survival and quality of life for patients with unmet medical needs. Using their years of regulatory experience, they identify de-risked, underappreciated dr-ugs and develop assets with an unmet medical need and leverage prior research toward high value clinical milestones and a lower risk of development failure.
And right now we've identified multiple potential catalysts that could help lead PCSA to a near term breakout. Here they are:
No. 1 - Low Float Volatility Could Be On Display (Daily)
No. 2 - A $9.00 Analyst Target Provides Over 300% Potential Upside From Tuesday's Close
No. 3 - Positive Results Could Mean Big Things Ahead For This Little-Known Biotech
No. 4 - Profile Trading Above 4 Key Lines Of Potential Support
But more on those in second...
The Skinny - Key Processa Pharmaceuticals Company Details
The leadership team behind Processa Pharmaceuticals, Inc. (Nasdaq:PCSA) was brought together by a common goal: to help patients suffering from life-threatening and life-compromising chronic diseases.
The starting point for all the company’s programs begins with unmet medical needs for patients and caregivers. Processa allocates its resources to accelerate development of these life improving solutions.
Working together for over 30 years, the leadership team has garnered a unique approach to develop therapies today through learning and applying their R&D and regulatory expertise to efficiently position dr-ugs for approval success.
Throughout their careers, the combined scientific, development and regulatory experience of the Processa team members have resulted in more than 30 dr-ug approvals by the FDA, over 100 meetings with the FDA, and involvement with more than 50 dr-ug development programs, including dr-ug products targeted to patients who have an unmet medical need.
Next Generation Capecitabine (NGC) (a combination of PCS6422 and capecitabine): The company has identified lower capecitabine dosage regimens when administered in NGC that will help avoid dose-limiting toxicities such as hand-foot syndrome, yet provide approximately 50-times greater potency than capecitabine alone.
Next Generation Capecitabine (NGC): Improved Efficacy
PCS6422 Irreversibly Inhibits DPD (Dihydropyrimidine Dehydrogenase Enzyme)